PATHOGENESIS OF ALS IN SOD1 TRANSGENIC MICE
PATHOGENESIS OF ALS IN SOD1 TRANSGENIC MICE
批准号:
2606040
负责人:
Robert H. Brown
金额:
$12.64万
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-04-15 至 2001-03-31
关键词:
active sites amyotrophic lateral sclerosis brain metabolism catalase chelation therapy copper electromyography enzyme activity genetically modified animals glutathione peroxidase hydrogen peroxide laboratory mouse nonhuman therapy evaluation pathologic process penicillamine superoxide dismutase thiocarbamate
中文摘要
这个项目的长期目标是调查
过量表达的转基因小鼠作为ALS动物模型的发病机制
突变型细胞内超氧化物歧化酶的表达及运动发育
神经元病。突变启动运动神经元的机制
死亡定义不明确{一种目前正在调查的假说
突变分子的异常折叠允许氢
过氧化氢与活性通道中的还原铜相互作用,从而
成为过氧化反应的底物。这种反应
在关键目标上产生有毒的羟基加合物。
我们将通过分析这种过氧化作用对
降低ALS小鼠疾病表型的措施
过氧化氢的过氧化作用。具体目标(1)是生成
双转基因小鼠同时具有突变型SOD1转基因和变异型
谷胱甘肽过氧化物酶水平(从零到超过正常水平的10倍)。
这些实验将决定是否加速清除
过氧化氢可以改善病程。具体目标(二)
将测试绑定和屏蔽(如果可访问)的可能性
突变活性中心中的铜会减少氢的进入
过氧化氢到这种金属上,从而延缓疾病。铜络合剂
试验包括青霉胺和二乙基二硫代氨基甲酸酯。老鼠会
监测发病时间和总存活率
有了这些干预措施。我们还将监测电生理
量化运动单位功能和活动水平的参数
脑和脊髓中的谷胱甘肽过氧化物酶和过氧化氢酶。我们
我相信这些实验将具有重要意义,因为它们将测试
两种关于神经毒性机制的特定假说
突变的SOD1和潜在的治疗这种致命疾病的策略。
英文摘要
The {long term objective} of this project is to investigate the
pathogenesis of ALS using as an animal model transgenic mice which over-
express mutant cytosolic superoxide dismutase (SOD) and develop motor
neuron disease. The mechanisms whereby mutations initiate motor neuron
death are not well defined {One hypothesis currently under investigation
is that} abnormal folding of the mutant molecule allows hydrogen
peroxide to interact with reduced copper in the active channel, thereby
becoming a substrate for a peroxidation reaction. This reaction
generates toxic hydroxyl adducts on critical targets.
We will test this peroxidation hypothesis by analyzing the effects on
the disease phenotype in ALS mice of measures which will reduce
peroxidation of hydrogen peroxide. Specific Aim (1) is to generate
doubly transgenic mice with both the mutant SOD1 transgene and varying
levels of glutathione peroxidase (from none to 10-fold above normal).
These experiments will determine whether accelerated clearance of
hydrogen peroxide can ameliorate the disease course. Specific Aim (2)
will test the possibility that binding and shielding if accessible
copper in the mutuant active site will reduce access of hydrogen
peroxide to this metal and thereby slow the disease. Copper chelators
to be tried include penicillamine and diethyldithiocarbamate. Mice will
be monitored for timing of onset of illness and overall survival without
and with these interventions. We will also monitor electrophysiological
parameters that quantitate motor unit function and activity levels of
glutahione peroxidase and {catalase} in brain and spinal cord. We
believe these experiments will be significant because they will test
both a specific hypothesis regarding the mechanism of neurotoxicity of
mutant SOD1 and a potential therapeutic strategy in this lethal disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Next-generation antisense therapeutics for ALS and frontotemporal dementia
-
批准号:10599901
-
项目类别:
-
资助金额:$63.51万
-
财政年份:2019
-
负责人:Robert H. Brown
-
依托单位:
Next-generation antisense therapeutics for ALS and frontotemporal dementia
-
批准号:9765950
-
项目类别:
-
资助金额:$66.04万
-
财政年份:2019
-
负责人:Robert H. Brown
-
依托单位:
Next-generation antisense therapeutics for ALS and frontotemporal dementia
-
批准号:10374767
-
项目类别:
-
资助金额:$63.51万
-
财政年份:2019
-
负责人:Robert H. Brown
-
依托单位:
Next-generation antisense therapeutics for ALS and frontotemporal dementia
-
批准号:9924676
-
项目类别:
-
资助金额:$63.51万
-
财政年份:2019
-
负责人:Robert H. Brown
-
依托单位:
Silencing C9or72 with rAAV Mediated RNAi
-
批准号:8767751
-
项目类别:
-
资助金额:$37.74万
-
财政年份:2014
-
负责人:Robert H. Brown
-
依托单位:
Silencing C9or72 with rAAV Mediated RNAi
-
批准号:9042441
-
项目类别:
-
资助金额:$36.05万
-
财政年份:2014
-
负责人:Robert H. Brown
-
依托单位:
Silencing C9or72 with rAAV Mediated RNAi
-
批准号:8853963
-
项目类别:
-
资助金额:$36.05万
-
财政年份:2014
-
负责人:Robert H. Brown
-
依托单位:
Silencing C9or72 with rAAV Mediated RNAi
-
批准号:9267549
-
项目类别:
-
资助金额:$46.41万
-
财政年份:2014
-
负责人:Robert H. Brown
-
依托单位:
High Throughput Screening for Compounds to Mitigate Toxicity of FUS/TLS & SOD1
-
批准号:8348533
-
项目类别:
-
资助金额:$53.91万
-
财政年份:2012
-
负责人:Robert H. Brown
-
依托单位:
High Throughput Screening for Compounds to Mitigate Toxicity of FUS/TLS & SOD1
-
批准号:8500486
-
项目类别:
-
资助金额:$47.9万
-
财政年份:2012
-
负责人:Robert H. Brown
-
依托单位:
High Throughput Screening for Compounds to Mitigate Toxicity of FUS/TLS & SOD1
-
批准号:8640222
-
项目类别:
-
资助金额:$48.58万
-
财政年份:2012
-
负责人:Robert H. Brown
-
依托单位:
High Throughput Screening for Compounds to Mitigate Toxicity of FUS/TLS & SOD1
-
批准号:8830481
-
项目类别:
-
资助金额:$43.07万
-
财政年份:2012
-
负责人:Robert H. Brown
-
依托单位:
Transgenic Mouse Models of FUS/TLS-Mediated Amyotrophic Lateral Sclerosis
-
批准号:7821236
-
项目类别:
-
资助金额:$49.99万
-
财政年份:2009
-
负责人:Robert H. Brown
-
依托单位:
Transgenic Mouse Models of FUS/TLS-Mediated Amyotrophic Lateral Sclerosis
-
批准号:7937835
-
项目类别:
-
资助金额:$49.97万
-
财政年份:2009
-
负责人:Robert H. Brown
-
依托单位:
Full Human Genome Sequencing in ALS
-
批准号:7855558
-
项目类别:
-
资助金额:$180.44万
-
财政年份:2009
-
负责人:Robert H. Brown
-
依托单位:
Full Human Genome Sequencing in ALS
-
批准号:7939625
-
项目类别:
-
资助金额:$180.39万
-
财政年份:2009
-
负责人:Robert H. Brown
-
依托单位:
CLINICAL TRIAL: PYRIMETHAMINE FOR TREATMENT OF SOD1 MEDIATED AMYLOTROPHIC LATERA
-
批准号:7731272
-
项目类别:
-
资助金额:$0.16万
-
财政年份:2008
-
负责人:Robert H. Brown
-
依托单位:
Development of New Therapeutics for Amyotrophic Lateral Sclerosis
-
批准号:7944010
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2007
-
负责人:Robert H. Brown
-
依托单位:
Development of New Therapeutics for Amyotrophic Lateral Sclerosis
-
批准号:7488977
-
项目类别:
-
资助金额:$15.73万
-
财政年份:2007
-
负责人:Robert H. Brown
-
依托单位:
Development of New Therapeutics for Amyotrophic Lateral Sclerosis
-
批准号:7208427
-
项目类别:
-
资助金额:$76.09万
-
财政年份:2007
-
负责人:Robert H. Brown
-
依托单位:
海外基金